Trelstar triptorelin pamoate regulatory update

FDA accepted for review an NDA from Watson for a 6-month formulation of 22.5 mg Trelstar triptorelin pamoate for palliative treatment of advanced prostate cancer. The company has U.S. and Canadian rig...